Extended Data Table 2 Summary of treatment emergent adverse events (TEAEs) in ≥10% of patients and grade ≥3 TEAEs in > 1 patient

From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial